Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Randomised controlled trial of a very brief nurse-delivered intervention followed by a digital intervention to support medication adherence and reduce blood pressure in people prescribed treatment for hypertension in primary care: protocol for the Programme on Adherence to Medication (PAM) trial.

NIHR open research·2026
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Inflammation PET and plasma neurofilament light predict survival in people with progressive supranuclear palsy.

Brain communications·2025
Same author

Immune Profiling in Early Cognitive Disorders (IMPRINT) study protocol: a longitudinal cohort study exploring biomarkers of inflammation in early dementia with Lewy bodies and Alzheimer's disease, as part of the Dementias Platform UK.

BMJ open·2025
Same author

The evolving therapeutic landscape of dementia with Lewy bodies.

The Lancet. Neurology·2025
Same author

Effects of Communicating Genetic Risk of Type 2 Diabetes and Wearable Technologies on Behavioral Outcomes in East Asians: Statistical Analysis Protocol for a Randomized Controlled Trial.

JMIR research protocols·2025
Same journal

Patient-derived forebrain cortical organoids reveal biphasic tau-MAP6-microtubule axis dysfunction in tauopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Genetic architecture of the limbic white matter microstructure in aging and Alzheimer's Disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Greater choroid plexus volume is linked to poor sleep, neurodegeneration, and cognitive deficits in older adults: Evidence from the IGNITE Study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Plasma-based neurobiological protein biomarkers as predictors of dementia progression: Insights from longitudinal aging study in India - Diagnostic assessment of dementia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Neuropathology-specific language features in primary progressive aphasia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Dementia blood biomarkers in the context of post-stroke cognitive outcomes: Systematic review and evidence synthesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Rozelle C Kane1, Leonidas Chouliaras2, Simon Griffin1

  • 1University of Cambridge, CAMBRIDGE, NA, United Kingdom.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 26, 2025
PubMed
概括
此摘要是机器生成的。

基于血液的生物标志物 (BBM) 显示出对痴呆和认知衰退的强大预测能力. 这些模型对于早期检测和干预是有价值的,即使在不同的初级保健环境中也是如此.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经科学和神经病学 神经科学和神经病学
  • 生物标志物发现发现
  • 流行病学 流行病学

背景情况:

  • 迫切需要适用于早期疾病阶段的痴呆风险模型.
  • 基于血液的生物标志物 (BBM) 是有希望的,但需要在一般人群中进行验证.
  • 早期干预,临床试验准入和初级保健诊断中BBM的潜力.

研究的目的:

  • 在纵向模型中系统地审查和元分析BBM的预测性能.
  • 评估BBM在初级保健环境中对痴呆症预测的有用性.
  • 为了评估不同环境和不同种类的人口的BBM绩效.

主要方法:

  • 对32项评估BBM纵向预测性能的研究进行了系统审查和元分析 (p-tau181,p-tau217,p-tau231,Aβ,GFAP,NfL).
  • 包括预先痴呆症人口报告预测性表现,使用接收器操作特征曲线 (AUROC) 下的面积.
  • 对研究环境,BBM组合,基线特征和结果 (疾病转化与认知衰退) 的敏感性分析.

主要成果:

  • 痴呆症转换的AUROC在记忆诊所为0.89,在社区环境中为0.85.
  • 模型显示症状与无症状个体的预测性能更高 (AUROC 0.89与0.79).
  • p-tau181的预测准确度很高,特别是在单标记模型 (AUROC 0.97) 和MCI转换为阿尔茨海默氏症痴呆症 (AUROC 0.91) 中.

结论:

  • 纵向BBM模型在异质环境中为发生性痴呆和认知衰退提供了可靠的预测.
  • 疾病的早期阶段为使用BBMs进行分层预测提供了机会.
  • 在初级保健中进行进一步的大规模观察试验对于验证和优化BBM模型用于现实世界的使用至关重要.